Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer
Sponsor: Daewoong Pharmaceutical Co. LTD.
Summary
A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer
Official title: A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants With Gastric Ulcer
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
384
Start Date
2026-10-15
Completion Date
2028-10-15
Last Updated
2026-07-28
Healthy Volunteers
No
Conditions
Interventions
DWP14012 40mg (Fexuprazan)
DWP14012 40mg(Fexuprazan) + placebo of Lansoprazole
Lansoprazole 30mg
Lansoprazole 30mg + Placebo of DWP14012 40mg
Locations (2)
RS Cipto Mangunkusumo
Jakarta, Indonesia
The Catholic University of Korea, Incheon St. Mary'S Hospital
Incheon, South Korea